USA - engelsk - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), sodium sulfate (unii: 0ypr65r21j) (sodium sulfate anhydrous - unii:36kcs0r750), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid for oral solution is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults. peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid for oral solution is contraindicated in the following conditions: -   gastrointestinal (gi) obstruction [see warnings and precautions (5.6)] -   bowel perforation [see warnings and precautions (5.6)] -   gastric retention -   ileus -   toxic colitis or toxic megacolon -   hypersensitivity to any ingredient in peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid for oral solution [see warnings and precautions (5.10)] risk summary there are no available data on peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid for oral solution in pregnant women to inform a drug-associated risk for adverse developmental

USA - engelsk - NLM (National Library of Medicine)

oceanside pharmaceuticals - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium sulfate (unii: 0ypr65r21j) (sodium sulfate anhydrous - unii:36kcs0r750), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - polyethylene glycol-3350, electrolytes, and ascorbate for oral solution is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults. polyethylene glycol-3350, electrolytes, and ascorbate for oral solution is contraindicated in the following conditions: risk summary there are no available data on polyethylene glycol-3350, electrolytes, and ascorbate for oral solution in pregnant women to inform a drug-associated risk for adverse developmental outcomes. animal reproduction studies have not been conducted with polyethylene glycol-3350, electrolytes, and ascorbate for oral solution. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary the

USA - engelsk - NLM (National Library of Medicine)

braintree laboratories, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium sulfate (unii: 0ypr65r21j) (sodium sulfate anhydrous - unii:36kcs0r750), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152), magnesium sulfate anhydrous (unii: ml30mj2u7i) (magnesium cation - unii:t6v3lhy838), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698) - suflave is indicated for the cleansing of the colon as a preparation for colonoscopy in adults. suflave is contraindicated in the following conditions: - gastrointestinal obstruction or ileus [see warnings and precautions ( 5.6)] - bowel perforation [see warnings and precautions ( 5.6)] - toxic colitis or toxic megacolon - gastric retention - hypersensitivity to any ingredient in suflave  [see warnings and precautions ( 5.8)] risk summary there are no available data on the use of suflave during pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride (suflave). the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other ad

USA - engelsk - NLM (National Library of Medicine)

salix pharmaceuticals, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium sulfate (unii: 0ypr65r21j) (sodium sulfate anhydrous - unii:36kcs0r750), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - polyethylene glycol 3350 100 g in 1 l - moviprep® is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults. moviprep is contraindicated in the following conditions: risk summary there are no available data on moviprep in pregnant women to inform a drug-associated risk for adverse developmental outcomes. animal reproduction studies have not been conducted with moviprep. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary there are no data available on the presence of moviprep in human milk, the effects of the drug on the breastfed child, or the effects of the drug on milk production. the lack of clinical data during lactation precludes a clear determination of the risk o

USA - engelsk - NLM (National Library of Medicine)

salix pharmaceuticals, inc - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium sulfate (unii: 0ypr65r21j) (sodium sulfate anhydrous - unii:36kcs0r750), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - plenvu® is indicated for cleansing of the colon in preparation for colonoscopy in adults. plenvu is contraindicated in the following conditions: risk summary there are no available data with plenvu in pregnant women to inform a drug-associated risk for adverse developmental outcomes. animal reproduction studies have not been conducted with plenvu. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary there are no data available to assess the presence of plenvu in human milk, the effects on the breastfed child or the effects on milk production. the lack of clinical data during lactation precludes a clear determination of the risk of plenvu to a child during lactation; therefore

USA - engelsk - NLM (National Library of Medicine)

strides pharma science limited - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37, bicarbonate ion - unii:hn1zra3q20), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - polyethylene glycol 3350 420 g in 4 l - polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution is indicated for bowel cleansing prior to colonoscopy in adults and pediatric patients aged 6 months or greater. polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution is contraindicated in the following conditions: - gastrointestinal (gi) obstruction, ileus, or gastric retention - bowel perforation - toxic colitis or toxic megacolon - known allergy or hypersensitivity to any component of polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution [see how supplied/storage and handling (16)] animal reproduction studies have not been conducted with polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution. it is also not known whether polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution can cause fetal harm when administered t

USA - engelsk - NLM (National Library of Medicine)

novel laboratories, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium sulfate anhydrous (unii: 36kcs0r750) (sodium sulfate anhydrous - unii:36kcs0r750), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - polyethylene glycol 3350 236 g in 274.31 g - peg-3350 and electrolytes for oral solution is indicated for bowel cleansing prior to colonoscopy and barium enema x-ray examination in adults. peg-3350 and electrolytes for oral solution is contraindicated in the following conditions: - gastrointestinal (gi) obstruction (5.6) - bowel perforation (5.6) - toxic colitis or toxic megacolon - gastric retention - ileus - hypersensitivity to components of peg-3350 and electrolytes for oral solution (5.8) animal reproduction studies have not been conducted with peg-3350 and electrolytes for oral solution. it is also not known whether peg-3350 and electrolytes for oral solution can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. peg-3350 and electrolytes for oral solution should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when peg-3350 and electrolytes for oral solution is administ

USA - engelsk - NLM (National Library of Medicine)

nexgen pharma, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p) - polyethylene glycol 3350 17 g - for the treatment of occasional constipation. this product should be used for 2 weeks or less or as directed by a physician. polyethylene glycol 3350 nf is contraindicated in patients with known or suspected bowel obstruction and patients known to be allergic to polyethylene glycol. there have been no reports of accidental overdosage. in the event of overdosage, diarrhea would be the expected major event. if an overdose of drug occurred without concomitant ingestion of fluid, dehydration due to diarrhea may result. medication should be terminated and free water administered. the oral ld50 is > 50 gm/kg in mice, rats and rabbits.

USA - engelsk - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p) - polyethylene glycol 3350 17 g in 17 g - for the treatment of occasional constipation. this product should be used for 2 weeks or less or as directed by a physician. polyethylene glycol 3350 nf is contraindicated in patients with known or suspected bowel obstruction and patients known to be allergic to polyethylene glycol.

USA - engelsk - NLM (National Library of Medicine)

lake erie medical & surgical supply dba quality care products llc - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p) - polyethylene glycol 3350 17 g in 17 g - for the treatment of occasional constipation. this product should be used for 2 weeks or less or as directed by a physician. polyethylene glycol 3350 nf is contraindicated in patients with known or suspected bowel obstruction and patients known to be allergic to polyethylene glycol.